Relatlimab/Nivolumab Shows Clinical Activity in Patients With Heavily Pretreated Advanced Melanoma
Patients with heavily pretreated advanced melanoma achieved responses with nivolumab and relatlimab.
Pierce Underscores the Importance of 2-Step Verification With Relatlimab/Nivolumab
Amber Pierce RN, BSN, OCN, highlights the importance of a 2-step verification process with fixed-dose regimen therapies.
Prophylaxis With Antibacterial Topical Treatment May Reduce Acute Radiation Dermatitis Severity
Research published in JAMA Oncology suggest that acute radiation dermatitis may be the result of a common skin bacterium and prevented with a low-cost topical treatment.
Krista Rubin Breaks Down Best Practices With Tebentafusp for Uveal Melanoma
Krista M. Rubin, RN, MS, FNP-BC, highlights how nurses can help patients with uveal melanoma anticipate and manage adverse events during the step-up dosing period with tebentafusp.
Cemiplimab Granted Full Approval For Metastatic Basal Cell Carcinoma
Cemiplimab has received full approval for patients with metastatic basal cell carcinoma. The most common adverse events include fatigue, musculoskeletal pain, rash, diarrhea, and anemia.
Gene Therapy Agent URO-902 Shows Promise in Helping Woman Manage Overactive Bladder and Urinary Incontinence
Phase 2a trial data suggest that single-dose URO-902 may be an effective, and safe, treatment for women experiencing difficulties with bladder control.
Ridad and McKaig Discuss Oncology Nurse Perceptions on Medical Cannabis
Improvements in Health Systems Model Reduces Disparities in Leukemia Survival in Low-Income Countries
Telephone and Web-Based Program Elicits Clinically Meaningful Results in Breast Cancer Survivors
Luspatercept Elicits High Transfusion Independence Rates in Lower-Risk MDS
